Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
Status:
Recruiting
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-control, phase III study to investigate
hetrombopag in subjects with severe AA who are treated naive.
180 treated naive patients with SAA will be enrolled in the study. The primary objective of
the study will be the rate of complete hematologic response at six months.